Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FNTA | P49354 | 14/20 | 0.59 |
| ▸ | FNTB | P49356 | 14/20 | 0.59 |
| ▸ | PGGT1B | P53609 | 4/20 | 0.51 |
| ▸ | IDO1 | P14902 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL7207857 | 0.89 | FNTA (0.67) | FNTAFNTBPGGT1B | |
| SCHEMBL5514757 | 0.81 | FNTA (0.80) | FNTAFNTBPGGT1BIDO1 | |
| SCHEMBL7203867 | 0.79 | FNTA (0.49) | FNTAFNTBPGGT1BIDO1 | |
| SCHEMBL5778239 | 0.75 | FNTA (0.68) | FNTAFNTBPGGT1BIDO1 | |
| SCHEMBL5733786 | 0.74 | FNTA (1.00) | FNTAFNTB | |
| SCHEMBL13186537 | 0.74 | FNTA (1.00) | FNTAFNTB | |
| SCHEMBL5777224 | 0.73 | FNTA (0.59) | FNTAFNTBPGGT1B | |
| SCHEMBL5783128 | 0.73 | FNTA (0.66) | FNTAFNTBPGGT1BIDO1 | |
| Hydrochloric Acid SCHEMBL5780158 | 0.71 | FNTA (0.64) | FNTAFNTBPGGT1BIDO1 | |
| SCHEMBL5778232 | 0.71 | FNTA (0.59) | FNTAFNTBPGGT1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0970079-B1 | FARNESYL TRANSFERASE INHIBITING 1,8-ANNELATED QUINOLINONE DERIVATIVES SUBSTITUTED WITH N- OR C-LINKED IMIDAZOLES | JANSSEN PHARMACEUTICA NV (BE) | 2003-10-01 | — | — | EP | disclosed |
| US-6444812-B1 | SUCH AS 7-(3-CHLOROPHENYL)-9-((4-CHLOROPHENYL)-1H-IMIDAZOL-1-YLMETHYL)-2,3-DIHYDRO -1H,5H-BENZO(IJ) QUINOLIZIN-5-ONE; FOR FORMING ONCOGENES FOR SIGNALLING TRANSFORMATION OF TUMOR CELLS | JANSSEN PHARMACEUTICA N.V. (BE) | 2002-09-03 | — | — | US | disclosed |
| US-20020049327-A1 | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles | VENET MARC GASTON (FR) | 2002-04-25 | — | — | US | disclosed |
| US-6187786-B1 | ANTITUMOR AND ANTICARCINOGENIC AGENTS | JANSSEN PHARMACEUTICA N.V. (BE) | 2001-02-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020049327-A1 | Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles | HCCS, CYP7A1, DHCR7 | FNTA 4/4885FNTB 5/4885PGGT1B 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.